Matt Hoffman

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD.

A cross-sectional, case-control study’s findings imply that patients with epilepsy may be experiencing high rates of psychological distress amid the COVID-19 pandemic.

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Pharmazz, the developer of the endothelin-B receptor agonist, noted that it plans to move forward with an investigational new drug submission to the FDA for sovateltide.

Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts.

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed the possible link between COVID-19 and stroke and offered an update on recent research in the stroke care landscape.

Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

The trio of authors from Johns Hopkins discussed the findings of a study that imply that BMI is associated with accelerated rates of ganglion cell and inner plexiform layer atrophy in those with multiple sclerosis.

The clinical neurology fellow at Brigham and Women's Hospital and Harvard University detailed what recent survey data suggest, why the survey was conducted, and how to possibly improve the approach to the protocol.

An identified association between accelerated rates of ganglion cell and inner plexiform layer atrophy in the absence of overt metabolic comorbidities suggests that obesity may affect accelerated neurodegeneration in those with multiple sclerosis.

Data showed that Ovid Therapeutics’ gaboxadol, also known as OV101, was well-tolerated and had a significant effect on secondary behavioral end points in the 3 combined study groups.

The positron emission tomography tau tracer was shown to identify high levels of Alzheimer disease neuropathologic change and neurofibrillary tangles with good sensitivity and specificity.

The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications.

The case-based reports ultimately suggest that more data collection is required, but highlight the observations of more than 60 patients, including a 5-patient cohort with Guillain-Barré syndrome.

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.

In an update to the 2016 practice advisory, new data have shifted recommendations to include the consideration of PFO closure for select patients under the age of 60.

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.

Vitalis’s VTS-Aspirin platform was granted an orphan drug designation to be used in combination with diroximel fumarate and monomethyl fumarate for the treatment of fumarate flush in relapsing multiple sclerosis.

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.

The Group Medical Director of Neuroscience at Genentech discussed the shorter, 2-hour infusion time for ocrelizumab and how it might impact multiple sclerosis care as a whole.